Mult-omics Palbociclib Resistance Study in HR+/HER2– Metastatic Breast Cancer
This study is multi-omics study of a Asian longitudinal metastatic breast cancer (MBC) cohort treated with palbociclib plus endocrine therapy. It contains NGS of baseline (BL) and progressive disease (PD) from 70 patients, consisting of 79 tumor/normal matched whole exome sequencing (WES) from 62 patients and 90 tumor whole transcriptome sequecing samples (WTS) from 70 patients. There were 56 BL biopsies profiled by WES and 64 by WTS; 23 PD biopsies were profiled by WES and 26 by WTS. Twenty and 23 patients had paired BL and PD biopsies profiled by WES and WTS, respectively.
- 228 samples
- DAC: EGAC00001002381
- Technology: Illumina HiSeq 2500
SMC Breast Cancer data transfer policy
To access raw data fastq, please contact SMC breast cancer DAC. (yhparkhmo@skku.edu or kyunghee.park@samsung.com). The process steps are: 1. Contact SMC breast cancer DAC to receive two applications. 1) Samsung Medical Center (SMC) Data Transfer Agreement (DTA) and 2) Questionnaire for DTA (Application form). 2. After reviewing the documents in your institution, fill in the blanks in two documents, sign and reply to SMC breast cancer DAC. 3. After receiving your signed documents, SMC internal committee will proceed with the approval process of data transfer. 4. SMC breast cancer DAC will contact EGA to grant access to the EGA dataset after obtaining permission from SMC internal committee.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |